These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408 [TBL] [Abstract][Full Text] [Related]
3. Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy. Belardinelli R; Capestro F; Misiani A; Scipione P; Georgiou D Eur J Cardiovasc Prev Rehabil; 2006 Oct; 13(5):818-25. PubMed ID: 17001224 [TBL] [Abstract][Full Text] [Related]
4. Update on implantable cardioverter defibrillators: knowing the differences in devices and their impact on patient care. Nichols K; Collins J AACN Clin Issues; 1995 Feb; 6(1):31-43. PubMed ID: 7736302 [TBL] [Abstract][Full Text] [Related]
5. Implantable cardioverter-defibrillator therapy in clinical practice. Cesario DA; Dec GW J Am Coll Cardiol; 2006 Apr; 47(8):1507-17. PubMed ID: 16630984 [TBL] [Abstract][Full Text] [Related]
7. Quality of life and psychological status of patients with implantable cardioverter defibrillators. Thomas SA; Friedmann E; Kao CW; Inguito P; Metcalf M; Kelley FJ; Gottlieb SS Am J Crit Care; 2006 Jul; 15(4):389-98. PubMed ID: 16823016 [TBL] [Abstract][Full Text] [Related]
8. Is implantable defibrillator indicated in all patients on cardiac resynchronization therapy? Pieragnoli P; Ricciardi G; Colella A; Musilli N; Porciani MC; Giaccardi M; Padeletti L; Michelucci A Minerva Cardioangiol; 2006 Dec; 54(6):735-41. PubMed ID: 17167385 [TBL] [Abstract][Full Text] [Related]
9. Reducing mortality with device therapy in heart failure patients without ventricular arrhythmias. Chapa DW; Lee HJ; Kao CW; Friedmann E; Thomas SA; Anderson J; Bardy GH Am J Crit Care; 2008 Sep; 17(5):443-52; quiz 453. PubMed ID: 18776000 [TBL] [Abstract][Full Text] [Related]
10. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations). Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697 [TBL] [Abstract][Full Text] [Related]
11. Effects of ICD implantation on quality-adjusted life years in patients with congestive heart failure. Ozasa N; Morimoto T; Furukawa Y; Shizuta S; Nishiyama K; Kita T; Kimura T Int J Cardiol; 2008 Jan; 123(2):213-6. PubMed ID: 17367883 [TBL] [Abstract][Full Text] [Related]
12. [Update on current care guidelines. Current care guideline: cardiac pacemaker therapy]. Duodecim; 2010; 126(4):391-2. PubMed ID: 20486489 [TBL] [Abstract][Full Text] [Related]
13. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator. Buxton AE Circulation; 2005 May; 111(19):2537-49; discussion 2537-49. PubMed ID: 15897357 [No Abstract] [Full Text] [Related]
14. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator. Moss AJ Circulation; 2005 May; 111(19):2537-49; discussion 2537-49. PubMed ID: 15900623 [No Abstract] [Full Text] [Related]
16. Indications to implantable cardioverter defibrillator in heart failure patients: a comment on the recently released ESC Guidelines on treatment and diagnosis of heart failure. Gasparini M; Breithardt G Eur Heart J; 2005 Nov; 26(22):2472-3; author reply 2473-4. PubMed ID: 16204261 [No Abstract] [Full Text] [Related]
17. Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. Shah B; Hernandez AF; Liang L; Al-Khatib SM; Yancy CW; Fonarow GC; Peterson ED; J Am Coll Cardiol; 2009 Feb; 53(5):416-22. PubMed ID: 19179199 [TBL] [Abstract][Full Text] [Related]
18. [Non-pharmacological treatment of heart failure: implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy]. van Gelder IC; Smit MD; Nieuwland W; van Veldhuisen DJ Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2238-44. PubMed ID: 17076357 [TBL] [Abstract][Full Text] [Related]
19. Device implant technique and consideration of body image: specific procedures for implantable cardioverter defibrillators in female patients. Sowell LV; Kuhl EA; Sears SF; Klodell CT; Conti JB J Womens Health (Larchmt); 2006 Sep; 15(7):830-5. PubMed ID: 16999638 [TBL] [Abstract][Full Text] [Related]
20. Effect of cardiac resynchronisation therapy on occurrence of ventricular arrhythmia in patients with implantable cardioverter defibrillators undergoing upgrade to cardiac resynchronisation therapy devices. Lin G; Rea RF; Hammill SC; Hayes DL; Brady PA Heart; 2008 Feb; 94(2):186-90. PubMed ID: 17761506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]